CEVEC Pharmaceuticals - now part of Cytiva

HIGH PERFORMANCE CELL TECHNOLOGIES FOR ADVANCED THERAPEUTICS

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Register for the online seminar hosted by @CEVEC1 now part of Cytiva during the BPI Digital Week on Nov 8, 10AM EDT and learn from VP Technology Development Dr Markus Krieger how you can produce high-titer, high-quality AAV vectors as easily as antibodies. https://t.co/I1dCGNqb0q

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

We are at #BIOEUROPE Oct 24–26 in Leipzig. Meet Nicole Faust, CEO, & Ulrich Kettling, CBO, via partneringONE to discuss our leading viral vector manufacturing technologies, ELEVECTA™ for stable AAV production & CAP™ Ad for RCA-free Adenoviral vectors. https://t.co/6szi9r6D1J

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

October is conference season, we're kicking it off with two exciting events: Meet @CEVEC1 at #ESGCT 29th Congress, 11-14 Oct in Edinburgh, UK
#CGMesa22, 11-13 Oct in Carlsbad, CA #genetherapy #viralvector #AAV #stableAAV #elevecta https://t.co/1RUrI6HDOG | https://t.co/RC8EF6QZil

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Today @CEVEC1 becomes part of #Cytiva, a global life sciences leader.
"We are excited to join Cytiva,” says Dr. Nicole Faust, #CEVEC’s CEO. “This enables new and powerful solutions for scalable (viral)vector manufacturing.“
https://t.co/f2DDq2a958
#genetherapy #cytiva #cevec

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

@CEVEC1 and @ROKOTELabs sign agreement on the use of CEVEC’s proprietary CAP® Ad Technology for the manufacturing of therapeutic and prophylactic vaccines for COVID-19 and other respiratory diseases. https://t.co/q5IJm5kWdv

#CAP #CAPAd #noRCA #RCAfree #Adeno #GeneTherapy

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Meet the @CEVEC team at booth #330 at BPI Biotech Week Boston, Sep 27 – 30. Listen to the talk of Michael Muehle, Head of Viral Vector Production on Sep 28, 3:00 p.m. EDT introducing “Next Level AAV manufacturing using stable ELEVECTA® producer cells”.
https://t.co/T8tNLpmhMY

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Our license partner @RZNOMICS, Inc. was granted IND approval for ph1/2a by the South Korean FDA for its lead gene therapy RZ001 targeting liver cancer. RZ001 is manufactured using @CEVEC’S CAP® Ad Technology for RCA-free Ad vectors.
#CAP #CAPAd #noRCA #RCAfree #GeneTherapy

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Don’t miss CEVEC’s CEO Dr. Nicole Faust discussing with industry experts topics from balancing competing interests to building trust at the @RegMedNet Panel “Developing successful advanced therapy partnerships” on July 5th, 10:00 a.m. EDT. Please register: https://t.co/P4nwn6PVcj

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Meet the CEVEC Team at 27th ESACT Meeting from June 27–29 in Lisbon and listen to the poster presentation “THE ELEVECTA HEK293 platform – An innovative, fully stable and helper virus-free AAV production system” https://t.co/PBzvztjMSP
#ELEVECTA #AAV #stableAAV #ESACT2022 #ESACT22

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Read the #BioPharmInternational article and learn about @CEVEC1’s newly developed process to drastically reduce product-related host cell DNA impurities during the production of recombinant adeno-associated virus-based vectors.
https://t.co/WgJDORNnoB
#AAV #GeneTherapy #ELEVECTA

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Catch the opportunity to meet us at #BIO2022 in San Diego at the @CEVEC1 booth No. 4507-09 and to schedule a meeting with CEO Dr. Nicole Faust, and CBO Dr. Ulrich Kettling using the conference partnering system. https://t.co/ICfdZ6wrMq
#ELEVECTA #GeneTherapy #AAV #stableAAV

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

CEVEC Head of Vector Production Inês do Carmo Gonçalves talked about “How to address challenges in producing #AAV vectors” at #ASGCT2022. “We truly believe #ELEVECTA to be the technology of choice to filling the gap in producing AAV vectors”. https://t.co/AWDrjxV7av
#GeneTherapy

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Meet us at #BIO2022 in San Diego from June 13 – 16 at the @CEVEC booth No. 4507-09. Schedule a meeting with Dr. Nicole Faust, CEO and Dr. Ulrich Kettling, CBO, using the conference partnering system. https://t.co/ICfdZ6wrMq
#ELEVECTA #GeneTherapy #AAV #stableAAV

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Only 10 days to go for the @ASGCT 25th Annual Meeting, May 16 – 19, 2022!
Meet the @CEVEC team at our booth #363, listen to the presentation and attend our poster session on stable helper-virus free #ELEVECTA® producer cells for #AAV vector manufacturing. https://t.co/ZrHPvuTImJ

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Our online seminar will present the latest developments in using stable AAV producer cell lines and explain how the ELEVECTA® system enables fully scalable vector production without plasmid transfection or helper viruses.
https://t.co/hq27X7XgZd
#ELEVECTA #AAV #stableAAV

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Hooray! In person again! Meet CEVEC at the Cell & Gene Meeting on the Med in Barcelona, Spain, from April 20-22. Listen to the presentation and request a meeting with Dr. Nicole Faust, CEO and Dr. Ulrich Kettling, CBO under: https://t.co/t640POHcZH
#CAPAd #ELEVECTA #GeneTherapy

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Meet the @CEVEC1 team at BIO-Europe Spring from March 28-31, 2022 and learn more about our industry-leading cell lines for RCA-free adenoviral vector production and AAV manufacturing based on stable cell lines.
#CAP #CAPAD #Adeno #ELEVECTA #AAV #stableAAV
https://t.co/dUBhMREweK

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Meet the @CEVEC1 Team at the 11th @ISBioTech Spring Meeting, Norfolk, VA. Listen to the talk of Dr. Tobias Bonifert on “Helper Virus-Free AAV Production Using Fully Stable Producer Cells” on March 14, 2:20–3:00 pm EST in the Viral Vectors & Vaccines track: https://t.co/AG1VBOvIdL

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Join @CEVEC’s FREE online seminar “Manufacturing of RCA-free adenoviral vectors” on Feb 22, 2022 - 08:00 PST; 11:00 EST; 16:00 BST; 17:00 CET hosted by Dr. Nico Scheer, Senior Consultant Business Development. Register here: https://t.co/yacySeVN9X
#RCAFreeAV #CAPAd #GeneTherapy

[CEVEC Pharmaceuticals - now part of Cytiva @CEVEC1]

Read about @CEVEC1 proprietary #CAP® Ad platform, an outstanding technology for RCA-free #adenovirus production combining excellent safety profile, industrial scalability and productivity, in recent articles featured by @GENbio and @BioProcessIntl: https://t.co/BPe9lT21Ex